Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Kobayashi, Takeshi ^a   Tanaka, Kensuke ^a   Fujita, Tetsuo ^a   Umezawa, Hiroki ^a   Amano, Hiroyuki ^a   Yoshioka, Kento ^a   Naito, Yusuke ^a   Hatano, Masahiko ^a   Kimura, Sadao ^a   Tatsumi, Koichiro ^a   Kasuya, Yoshitoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PHOSPHOPROTEIN; PROTEIN KINASE B; STAT3 PROTEIN;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL FATE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; INFLAMMATION; LUNG ALVEOLUS CELL TYPE 2; LUNG FIBROSIS; LUNG HOMOGENATE; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE SECTION; UPREGULATION; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS;

EID: 84939538294     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0261-z     Document Type: Article

References (56)

1. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949-61.
2. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355-61.
3. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov. 2010;9:129-40.
4. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40:362-82.
5. Yamauchi K, Kasuya Y, Kuroda F, Tanaka K, Tsuyusaki J, Ishizaki S, et al. Attenuation of lung inflammation and fibrosis in CD69-deficient mice after intratracheal bleomycin. Respir Res. 2011;12:131.
6. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest. 2004;114:291-9.
7. Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, Kawasuji M, et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol. 2004;204:594-604.
8. Okazaki T, Nakao A, Nakano H, Takahashi F, Takahashi K, Shimozato O, et al. Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J Immunol. 2001;167:1977-81.
9. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJD, Morris D, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA. 2000;97:1778-83.
10. Craig VJ, Quintero PA, Fyfe SE, Patel AS, Knolle MD, Kobzik J, et al. Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury. J Immunol. 2013;190:4283-96.
11. King Jr TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164:1171-81.
12. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol. 2011;163:141-72.
13. Günther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev. 2012;21:152-60.
14. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA. 2006;103:13180-5.
15. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181:254-63.
16. Lawson WE, Cheng DS, Degryse AL, Tanjorea H, Polosukhina VV, Xua XC, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA. 2011;108:10562-7.
17. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA. 2007;104:7552-7.
18. Boucher RC. Idiopathic pulmonary fibrosis - a sticky business. N Engl J Med. 2011;364:1560-1.
19. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol. 2008;38:566-71.
20. O'Donoghue RJJ, Knight DA, Richards CD, Prêle CM, Lau HL, Jarnicki AG, et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med. 2012;4:939-51.
21. Pedroza M, Schneider DJ, Karmouty-Quintana H, Coote J, Shaw S, Corrigan R, et al. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLOS ONE. 2011;6, e22667.
22. Le T-TT, Karmouty-Quintana H, Melicoff E, Le T-TT, Weng T, Chen N-Y, et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol. 2014;193:3755-68.
23. Kida H, Yoshida M, Hoshino S, Inoue K, Yano Y, Yanagita M, et al. Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol. 2005;288:L342-9.
24. Matsuzaki Y, Besnard V, Clark JC, Xu Y, Wert SE, Ikegami M, et al. STAT3 regulates ABCA3 expression and influences lamellar body formation in alveolar type II cells. Am J Respir Cell Mol Biol. 2008;38:551-8.
25. Takanami-Ohnishi Y, Asada S, Tsunoda H, Fukamizu A, Goto K, Yoshikawa H, et al. Possible involvement of p38 mitogen-activated protein kinase in decidual function in parturition. Biochem Biophys Res Commun. 2001;288:1155-61.
26. Messier EM, Mason RJ, Kosmider B. Efficient and rapid isolation and purification of mouse alveolar type II epithelial cells. Exp Lung Res. 2012;38:363-73.
27. Tanaka K, Fujita T, Umezawa H, Namiki K, Yoshioka K, Hagihara M, et al. Therapeutic effect of lung mixed culture-derived epithelial cells on lung fibrosis. Lab Invest. 2014;94:1247-59.
28. Huübner R-H, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. BioTechniques. 2008;44:507-17.
29. Liu W, Wan J, Han J-Z, Li C, Feng D-D, Yue S-J, et al. Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice. Respir Res. 2013;14:101.
30. Ataie-Kachoie P, Pourgholami MH, Morris DL. Inhibition of the IL-6 signaling pathway: A strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth F R. 2013;24:163-73.
31. Lasserre R, Guo X-J, Conchonaud F, Hamon Y, Hawchar O, Bernard A, et al. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008;4:538-47.
32. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013;5:a008656.
33. Chuquimia OD, Petursdottir DH, Rahman MJ, Hartl K, Singh M, Fernández C. The role of alveolar epithelial cells in initiating and shaping pulmonary immune responses: communication between innate and adaptive immune systems. PLOS ONE. 2012;7, e32125.
34. Tokuhara N, Namiki K, Uesugi M, Miyamoto C, Ohgoh M, Ido K, et al. N-type calcium channel in the pathogenesis of experimental autoimmune encephalomyelitis. J Biol Chem. 2010;285:33294-306.
35. Namiki K, Matsunaga H, Yoshioka K, Tanaka K, Murata K, Ishida J, et al. Mechanism for p38aα-mediated experimental autoimmune encephalomyelitis. J Biol Chem. 2012;287:24228-38.
36. Breitkopf SB, Yuan M, Pihan GA, Asara JM. Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS). Proc Natl Acad Sci USA. 2012;109:16190-5.
37. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8 Suppl 2:S2.
38. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis. 1997;176:439-44.
39. Crestani B, Cornillet P, Dehoux M, Rolland C, Geunounou M, Aubier M. Alveolar type II epithelial cells produce interleukin-6 in vitro and in vivo. Regulation by alveolar macrophage secretory products. J Clin Invest. 1994;94:731-40.
40. Kim S, Lee J, Jang B-C, Kwon TK, Park J-W. BAI, A novel cyclin-dependent kinase inhibitor induces apoptosis in A549 cells through activation of caspases and inactivation of Akt. J Cell Biochem. 2013;114:282-93.
41. Bao S, Wang Y, Sweeney P, Chaudhuri A, Doseff AI, Marsh CB, et al. Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;288:L36-42.
42. Xu Y, Ikegami M, Wang Y, Matsuzaki Y, Whitsett JA. Gene expression and biological processes influenced by deletion of Stat3 in pulmonary type II epithelial cells. BMC Genomics. 2007;8:455.
43. Moore BB, Coffey MJ, Christensen P, Sitterding S, Ngan R, Wilke CA, et al. GM-CSF regulates bleomycin-Induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol. 2000;165:4032-9.
44. Arras M, Louahed J, Heilier J-F, Delos M, Brombacher F, Renauld J-C, et al. IL-9 protects against bleomycin-induced lung injury. Involvement of prostaglandins. Am J Pthol. 2005;166:107-15.
45. Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002;27:419-27.
46. Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1038-44.
47. Segel MJ, Aqeilan R, Zilka K, Lorberboum-Galski H, Wallach-Dayan SB, Conner MW, et al. Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury. Int J Exp Path. 2005;86:279-88.
48. Murata S, Hashimoto I, Nakano Y, Myronovych A, Watanabe M, Ohkohchi N. Single administration of thrombopoietin prevents progression of liver fibrosis and promotes liver regeneration after partial hepatectomy in cirrhotic rats. Ann Surg. 2008;248:821-8.
49. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CRR, Capelozzi VL. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol. 2001;54:132-8.
50. Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, Stampfli M, et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol. 2004;173:2099-108.
51. Li M, Krishnaveni MS, Li C, Zhou B, Xing Y, Banfalvi A, et al. Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J Clin Invest. 2011;121:277-87.
52. Moodley YP, Misso NL, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ, et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol. 2003;29:490-8.
53. Wong S, Botelho FM, Rodrigues RM, Richards CD. Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 dysregulation in lungs of fibrosis-resistant BALB/c mice. Lab Invest. 2014;94:1003-16.
54. Tanaka T, Kishimoto T. Targeting interleukin-6: All the way to treat autoimmune and inflammatory diseases. Int J Biol Sci. 2012;8:1227-36.
55. Kawashiri S, Kawakami A, Sakamoto N, Ishimatsu Y, Eguchi K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int. 2012;32:4023-6.
56. Wendling D, Vidon C, Godfrin-Valnet M, Rival G, Guillot X, Prati C. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine. 2013;80:670-1.